Millennium Pharma Reports Higher Complete Remission Rates From Phase I/II Study Of Combination Therapy VELCADE In Multiple Myeloma Patients - Quick Facts

(RTTNews) - Millennium Pharmaceuticals, Inc. (MLNM | news | PowerRating | PR Charts ) announced the publication of updated results of the Phase I/II clinical trial of the combination therapy VELCADE, melphalan and prednisone, or VcMP, in newly diagnosed multiple myeloma patients.

Results of this study included one of the highest reported complete remission, or CR, rates, which is an important indicator for long-term survival. Results also included the highest three- year survival rate reported in the non-transplant setting.

Results showed an immunofixation-negative CR rate of 32% and an overall response rate of 89% with VcMP. The overall survival rate at 38 months was 85% with VcMP compared to the 38% historical control with melphalan and prednisone.

For comments and feedback: contact editorial@rttnews.com Copyright(c) 2008 RealTimeTraders.com, Inc. All Rights Reserved

More News:   Market Updates | Stock Alerts | All Trading News | Stock Index